Literature DB >> 16198828

Characterization of pure high-grade DCIS on magnetic resonance imaging using the evolving breast MR lexicon terminology: can it be differentiated from pure invasive disease?

Ashley M Groves1, Ruth M L Warren, Sarah Godward, Pauline S Rajan.   

Abstract

Magnetic resonance imaging (MRI) is now a recognized method of imaging the breast. Unfortunately, there is lack of standardization in the MRI terminology used to characterize the appearance of breast lesions. Moreover, cases of mixed histologies are often imaged. We retrospectively identified cases of pure high-grade ductal carcinoma in situ (DCIS) using the recently introduced breast MRI lexicon and characterized the lesions in order to try and identify features that might distinguish high-grade DCIS from invasive disease. Five-year review of our institution's database revealed 637 patients underwent gadolinium-enhanced breast MRI examination. Twenty patients had histologically proven pure high-grade DCIS. After excluding patients with previous chemotherapy or inadequate MRI examination, 13 patients were analyzed and compared to the 13 most recent cases of pure invasive breast carcinoma. The morphological and dynamic features were then compared. High-grade DCIS cases were significantly more likely to show focal branching pattern (P=.03) and to have an irregular contour (P=.03), compared with invasive disease. Although of marginal statistical significance, DCIS lesions are more likely to have a lower morphological score than invasive carcinoma (P=.06), whilst the latter is more likely to show ring enhancement (P=.07). Use of breast MRI for staging at our institution shows that pure DCIS and pure invasive cancers are both rare entities. Despite the relatively limited numbers, we identified features that would help to differentiate high-grade DCIS from invasive carcinoma on MRI.

Entities:  

Mesh:

Year:  2005        PMID: 16198828     DOI: 10.1016/j.mri.2005.06.003

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  6 in total

1.  MRI of the breast in patients with DCIS to exclude the presence of invasive disease.

Authors:  Eline E Deurloo; Jincey D Sriram; Hendrik J Teertstra; Claudette E Loo; Jelle Wesseling; Emiel J Th Rutgers; Kenneth G A Gilhuijs
Journal:  Eur Radiol       Date:  2012-02-26       Impact factor: 5.315

2.  Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.

Authors:  Anjali S Kumar; Daniel F Chen; Alfred Au; Yunn-Yi Chen; Jessica Leung; Elisabeth R Garwood; Jessica Gibbs; Nola Hylton; Laura J Esserman
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

3.  The diverse pathology and kinetics of mass, nonmass, and focus enhancement on MR imaging of the breast.

Authors:  Sanaz A Jansen; Akiko Shimauchi; Lindsay Zak; Xiaobing Fan; Gregory S Karczmar; Gillian M Newstead
Journal:  J Magn Reson Imaging       Date:  2011-06       Impact factor: 4.813

4.  Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model.

Authors:  Sanaz A Jansen; Tatjana Paunesku; Xiaobing Fan; Gayle E Woloschak; Stefan Vogt; Suzanne D Conzen; Thomas Krausz; Gillian M Newstead; Gregory S Karczmar
Journal:  Radiology       Date:  2009-11       Impact factor: 11.105

5.  The effects of applying breast compression in dynamic contrast material-enhanced MR imaging.

Authors:  Riham H El Khouli; Katarzyna J Macura; Ihab R Kamel; David A Bluemke; Michael A Jacobs
Journal:  Radiology       Date:  2014-03-12       Impact factor: 11.105

6.  Characterization of Pure Ductal Carcinoma In Situ on Dynamic Contrast-Enhanced MR Imaging: Do Nonhigh Grade and High Grade Show Different Imaging Features?

Authors:  Siwa Chan; Jeon-Hor Chen; Garima Agrawal; Muqing Lin; Rita S Mehta; Philip M Carpenter; Orhan Nalcioglu; Min-Ying Su
Journal:  J Oncol       Date:  2010-09-21       Impact factor: 4.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.